




Anti arrhythmic

- **Cardiac arrhythmias**

- Deviation from normal pattern of cardiac rhythm.
- Normal heart beat is 60-100 beats/min.







<b>SNO</b>	<b>cardiac arrhythmias</b>	<b>condition</b>
1	Extrasystoles (ES)	premature ectopic beats due to abnormal automaticity
2	Paroxysmal supraventricular tachycardia (PSVT)	150–200/min
3	Atrial flutter (AFI)	200– 350/min
4	Atrial fibrillation (AF)	350–550/min
5	Ventricular tachycardia (VT)	4 or more consecutive ventricular extrasystoles
6	Torsades de pointes	life-threatening form of polymorphic ventricular tachycardia (with long Q-T interval.)
7	Atrio-ventricular (A-V) block	depression of impulse conduction through the A-V node and bundle of His
8	Ventricular fibrillation (VF)	irregular, rapid and fractionated activation of ventricles resulting in incoordinated contraction of its fibres with loss of pumping function

- Antiarrhythmic drugs are used to treat abnormal cardiac rhythms such as atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, etc.
- There are several different classes of antiarrhythmic medications and they act on different phases of cardiac myocyte and/or pacemaker cell action potentials.

# THE VAUGHAN WILLIAMS CLASSIFICATION SYSTEM FOR ANTIARRHYTHMIC THERAPY

CLASS	TYPE	DRUGS
I	Sodium channel blockers	
	CLASS I A	Quinidine, Procainamide, Disopyramide
	CLASS I B	Lidocaine, Mexiletine
	CLASS I C	Propafenone, Flecainide
II	Beta blockers	Propranolol, Esmolol, Sotalol
III	Potassium channel blockers	Amiodarone, Dronedarone, Dofetilide, Ibutilide
IV	Calcium channel blockers	Verapamil, Diltiazem
V	Miscellaneous	Adenosine, Digoxin

**Class I**

**Sodium-channel blocker**

Ia (moderate): quinidine, procainamide  
Ib (weak): lidocaine, mexiletine  
Ic (strong): flecainide, propafenone

**Class IV**

**Calcium-channel blocker**

Verapamil  
Diltiazem

**Class III**


**Potassium-channel blocker**

Amiodarone  
Sotalol

**Class II**

**Beta-blocker**

Propranolol  
Metoprolol






## Sodium channel blockers:

- sodium channel blockers decrease the slope of phase 0, and the depolarization rate and amplitude will be reduced.
- Cardiac myocyte conduction velocity and transmission will be decreased as a result.
- This will decrease atrial and ventricular myocyte excitability and serve to suppress abnormal conduction rhythms.
- Since pacemaker cells use calcium ions to depolarize, sodium channel blockers have little effect on the SA node and AV node (pacemaker cells).

# Sodium Channel Blockers

Atrial & Ventricular  
Myocytes




- Sodium channel blockers act on phase 0 of non-pacemaker cardiac myocyte action potentials by blocking the influx of sodium ions into the cell.
- This decreases depolarization rate and amplitude thereby decreasing myocyte conduction velocity and transmission.

## **Class IA (Quinidine, Procainamide, Disopyramide)**

- These drugs blocks myocardial  $\text{Na}^+$  channels in the open state—reduces automaticity and maximal rate of 0 phase depolarization in a frequency dependent manner.
- Prolongation of APD is due to  $\text{K}^+$  channel block, while lengthening of ERP is caused by its moderate effect on recovery of  $\text{Na}^+$  and  $\text{K}^+$  channels.
- At high concentrations it also inhibits L type  $\text{Ca}^{2+}$  channels. Quinidine decreases the availability of  $\text{Na}^+$  channels as well as delays their reactivation

**Class IA drugs slow Phase 0 depolarization, prolong action potential, and slow conduction.**



# Quinidine

## **Side effects:**

- hypotension,
- GI problems (diarrhea and vomiting), and
- cinchonism (tinnitus, blurred vision, and headaches).

## **Drug interaction:**

- Marked fall in BP in patients receiving vasodilators.
- Risk of *torsades de pointes* is increased by hypokalaemia caused by diuretics.
- Synergistic cardiac depression with  $\beta$ -blockers, verapamil, K<sup>+</sup> salts.

**Use:**

*Atrial and ventricular arrhythmias*

**Dose:**

QUINIDINE SULPHATE 200 mg tab; QUININGA 300 mg tab,  
600 mg/2 ml inj; NATCARDINE 100 mg tab.

## **Procainamide:**

It is orally active amide derivative of the local anaesthetic procaine, with cardiac electrophysiological actions almost identical to those of quinidine, *viz. slowing of 0 phase depolarization* and impulse conduction, prolongation of APD, ERP, QRS complex and Q-T interval.



## **Adverse effects:**

- nausea and
- vomiting do occur.
- weakness,
- mental confusion and hallucinations are noted at higher doses.
- Flushing
- *torsades de pointes*
- Long-term high dose procainamide therapy can cause systemic lupus erythematosus (SLE)

### **Use :**

monomorphic VT and some supraventricular arrhythmias

### **Dose:**

PRONESTYL 250 mg tab., 1 g/10 ml inj.

### **Disopyramide:**

It is a quinidine like Class IA drug that has prominent cardiac depressant and anticholinergic Actions

### **Adverse effects :**

- dry mouth,
- constipation,
- urinary retention (especially in elderly males) and blurred vision

### **Use:**


- ventricular arrhythmia

**Dose:** *100–150 mg 6–8 hourly oral.*

NORPACE 100, 150 mg cap, REGUBEAT 100 mg tab.

# Class I B

- These drugs block Na<sup>+</sup> channels more in the inactivated than in the open state, but do not delay channel recovery (channel recovery time < 1S).
- They do not depress A-V conduction or prolong (may even shorten) APD, ERP and Q-T.
- They shorten Phase 3 repolarization
- ↓ the duration of the cardiac action potential
- They suppress arrhythmias caused by abnormal automaticity
- They show *rapid association & dissociation* (weak effect) with Na<sup>+</sup> channels with appreciable degree of use-dependence
- No effect on conduction velocity



## Pharmacokinetics :

Lidocaine is inactive orally due to high first pass metabolism in liver.

## Dose:

- XYLOCARD, GESICARD 20 mg/ml inj. (5, 50 ml vials)

## **Adverse effects :**

- Drowsiness,
- nausea,
- paresthesias,
- blurred vision,
- disorientation,
- nystagmus,
- twitchings and fits.

## **USES:**

- Ventricular tachycardia
- Ventricular fibrillation

## **Mexiletine:**

It is a local anaesthetic and an orally active antiarrhythmic;

## **Side effects:**

- Tremor
- Nausea
- Vomitting

## **Uses:**

- ventricular arrhythmias


## **Dose:**

MEXITIL 50, 150 mg caps, 250 mg/10 ml. inj.

# CLASS I C

- They **markedly slow Phase 0** fast depolarization
- They markedly slow conduction in the myocardial tissue
- They possess **slow rate of association and dissociation (strong effect)** with sodium channels
- They only have **minor effects on the duration of action potential and refractoriness**
- They reduce automaticity by increasing the threshold potential rather than decreasing the slope of Phase 4 spontaneous depolarization.

**Class IC drugs  
markedly slow  
Phase 0 depolarization.**





## **Propafenone:**

### **Side effects :**

- Nausea,
- Vomiting,
- Bitter taste,
- Constipation and
- Blurred vision.

### **uses:**

- for prophylaxis and treatment of ventricular arrhythmias and
- tachycardia

**Dose:** *150 mg BD–300 mg TDS;*

RHYTHMONORM 150 mg tab.

- Class Ia agents act at intermediate speed and include quinidine and procainamide.
- Class Ib agents are the fastest acting and include lidocaine and mexiletine.
- Finally, class Ic agents such as flecainide work by slow sodium channel association and dissociation.

# CLASS II (Beta blockers)

## Mechanism of action:

- Negative inotropic and chronotropic action.
- Prolong AV conduction (delay)
- Diminish phase 4 depolarization → suppressing automaticity (of ectopic focus)

## Clinical indications:

- Beta-blockers are useful in the management of tachyarrhythmias not only as treatment and prevention, but also offering rate control in AF and atrial flutter.
- chronic heart failure (HF),
- glaucoma
- MI.
- Certain non-cardioselective agents (*eg carvedilol and propranolol*) are *useful in* anxiety and tremor.

## **Contraindications:**

- The main contraindication to beta-blockade is obstructive lung disease (*ie asthma*), due to the risk of bronchoconstriction.

## **Adverse effects:**

- Fatigue and
- sleep disturbance.

## **Dose:**

MINIBLOCK 100 mg/10 ml, 250 mg/10 ml inj.;

# CLASS III (Potassium channel blockers)

## Mechanism of action:

- Potassium channels are responsible for cardiomyocyte repolarisation through potassium efflux, allowing electrical conduction of an action potential through the heart.
- Blockage of these channels to prevent potassium release slows repolarisation by increasing action potential and refractory period duration and slowing conduction, translating as a prolonged QT interval on the ECG.
- The most commonly used class III agents are amiodarone, sotalol and dronedarone, although all have crossover actions: amiodarone having some class I, II and IV activity, sotalol non-selective class II activity, and dronedarone class I, II, III and IV activity.

## **Uses:**

- Atrial and ventricular tachyarrhythmias.

## **Side effects:**

- Chest pain,
- Breathlessness and
- Palpitations.

# Class IV agents – calcium-channel blockers

- Calcium channel blockers decrease inward  $\text{Ca}^{2+}$  currents resulting in a decrease of phase 4 spontaneous depolarization (SA node)
- They slow conductance in  $\text{Ca}^{2+}$  current-dependent tissues like AV node.
- Examples: verapamil & diltiazem
- Because they act on the heart only and not on blood vessels.
- Dihydropyridine family are not used because they only act on blood vessels

## **Mechanism of action:**

The non-dihydropyridine calcium-channel blockers (diltiazem and verapamil) prevent influx of calcium into cardiomyocytes, thereby decreasing conduction through the AV node and overall cardiac contractility.

## **Uses:**

- Non-dihydropyridines are predominantly used in the prevention and treatment of supraventricular tachycardia (SVT).

## **Contraindications:**

- As class IV agents reduce cardiac contractility, they are contraindicated in HF



## **Adverse effects :**

- bradycardia,
- AV block,
- dizziness,
- flushing and
- headaches.
- Verapamil may additionally cause constipation, rash and nausea.

# ADENOSINE

- It activates ACh sensitive  $K^+$  channels and causes membrane hyperpolarization through interaction with A1 type of adenosine GPCRs on SA node (pacemaker depression  $\rightarrow$  bradycardia), A-V node (prolongation of ERP  $\rightarrow$  slowing of conduction) and atrium (shortening of AP, reduced excitability).
- It indirectly reduces  $Ca^{2+}$  current in A-V node. Depression of the reentrant circuit through A-V node is responsible for termination of majority of PSVTs.

## **Uses :**

Paroxysmal supra ventricular tachycardia

## **Adverse effects:**

transient dyspnoea, chest pain, fall in BP and flushing in 30–60% patients;

## **Dose:**

ADENOJECT, ADENOCOR 3 mg adenosine (base) per ml in 2 ml and 10 ml amp.